| Literature DB >> 29507399 |
Anastasia Oikonomou1, Farzad Khalvati2, Pascal N Tyrrell3, Masoom A Haider2, Usman Tarique2, Laura Jimenez-Juan2, Michael C Tjong4, Ian Poon4, Armin Eilaghi2, Lisa Ehrlich2, Patrick Cheung4.
Abstract
We sought to quantify contribution of radiomics and SUVmax at PET/CT to predict clinical outcome in lung cancer patients treated with stereotactic body radiotherapy (SBRT). 150 patients with 172 lung cancers, who underwent SBRT were retrospectively included. Radiomics were applied on PET/CT. Principal components (PC) for 42 CT and PET-derived features were examined to determine which ones accounted for most of variability. Survival analysis quantified ability of radiomics and SUVmax to predict outcome. PCs including homogeneity, size, maximum intensity, mean and median gray level, standard deviation, entropy, kurtosis, skewness, morphology and asymmetry were included in prediction models for regional control (RC) [PC4-HR:0.38, p = 0.02], distant control (DC) [PC4-HR:0.51, p = 0.02 and PC1-HR:1.12, p = 0.01], recurrence free probability (RFP) [PC1-HR:1.08, p = 0.04], disease specific survival (DSS) [PC2-HR:1.34, p = 0.03 and PC3-HR:0.64, p = 0.02] and overall survival (OS) [PC4-HR:0.45, p = 0.004 and PC3-HR:0.74, p = 0.02]. In combined analysis with SUVmax, PC1 lost predictive ability over SUVmax for RFP [HR:1.1, p = 0.04] and DC [HR:1.13, p = 0.002], while PC4 remained predictive of DC independent of SUVmax [HR:0.5, p = 0.02]. Radiomics remained the only predictors of OS, DSS and RC. Neither SUVmax nor radiomics predicted recurrence free survival. Radiomics on PET/CT provided complementary information for prediction of control and survival in SBRT-treated lung cancer patients.Entities:
Mesh:
Year: 2018 PMID: 29507399 PMCID: PMC5838232 DOI: 10.1038/s41598-018-22357-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of the patients, lesions and treatment.
| Patients | 150 |
| Male/Female | 73/77 |
| Age | 74 (46–92) |
| T-stage | |
| T1aN0 | 62 |
| T1bN0 | 51 |
| T2aN0 | 33 |
| T2bN0 | 2 |
| T3 N0 | 25 |
| Histology | 130 |
| Adenocarcinoma | 69 (including 5 former BAC) |
| Squamous | 37 |
| large cell | 1 |
| NSCLC undifferentiated | 11 |
| non-diagnostic biopsy | 12 |
| Not biopsy proven – | 42 |
| Size (cm) | 2.4 (0.7–5.8) |
| Location | |
| Upper | 102 (59.3%) |
| Middle | 11 (6.39%) |
| Lower | 59 (34.3%) |
| Patients w 1 lesion | 130 |
| Patients w 2 lesions | 18 |
| Patients w 3 lesions | 2 |
| Follow-up period (mo) | Mean: 28 (3–66), Median: 27 |
| Total dose – Gy (nr pts) | |
| 48 | 107/172 |
| 52 | 51/172 |
| 50 | 13/172 |
| 56 | 1/172 |
| Outcomes at 2 years | |
| local control (LC) | 95% (CI: 91–99%) |
| lobar control (LOBC) | 92% (CI: 87–97%) |
| regional control (RC) | 90% (CI: 85–95%) |
| distant control (DC) | 75% (CI: 67–83%) |
| recurrence free probability (RFP) | 69% (CI: 62–77%) |
| recurrence free survival (RFS) | 69% (CI: 61–77%) |
| overall survival (OS) | 79% (CI: 72–86%) |
| disease specific survival (DSS) | 88% (CI: 82–93%) |
Clinical outcome/Survival analysis with Principal components and without or with SUVmax.
| OS | RFP | DC | RC | DSS | |
|---|---|---|---|---|---|
| Without SUVmax | PC 4 | SEX | PC 4 | PC 4 | PC 2 |
| PC 3 | PC 1 | PC 1 | PC 3 | ||
| With SUVmax | PC 4 | SEX | PC 4 | PC 4 | PC 2 |
| PC 3 | SUV | SUV | PC 3 |
OS: Overall survival, RFP: Recurrence free probability, DC: Distant control, RC: Regional control, DSS: Disease specific survival.
Summary of texture feature groups.
| Feature group | Number of features | Description |
|---|---|---|
| Statistical-First order[ | 8 | Region of interest Size_# of pixels (ROI Size), Mean gray level, Standard Deviation (SD), Median gray level, Region of interest_Minimum pixel intensity (ROI Min), Region of interest_Maximum pixel intensity (ROI Max), Kurtosis, Skewness |
| Textural-Second order[ | 6 | Contrast, Energy, Correlation, Homogeneity, Entropy, Normalized Entropy |
| Morphology[ | 3 | Area regularity (1), perimeter regularity (2) |
| Asymmetry[ | 4 | Region bilateral symmetry (4) |
Significant Principal Components of Textural features based on PET/CT.
| PC | PC1 | PC2 | PC3 | PC4 |
|---|---|---|---|---|
| Statistical-First order | ROI max pixel intensity | ROI max pixel intensity | ROI max pixel intensity | Kurtosis |
| ROI size | Standard Deviation | Mean Gray Level | Skewness* | |
| Mean Gray Level | Mean Gray Level | Median Gray Level | ||
| Median Gray Level | Standard Deviation | |||
| Standard Deviation | ||||
| Textural-Second order | Homogeneity | Homogeneity | ||
| Normalized Entropy* | Normalized Entropy | |||
| Entropy* | ||||
| Morphologic | Asymmetry1 | Morphology2 | Morphology1 | |
| Asymmetry2 | Asymmetry1* | Morphology1 | ||
| Asymmetry3 | Asymmetry3* | Morphology2* | ||
| Asymmetry4 |
“*”Indicates the negative correlation of the specific feature.
Figure 1Kaplan-Meier survival curves for overall survival (OS). Subgroups of low and high risk were determined by a cut-off value of −0.71 for PC4 (logrank chi-square: 7.39, p = 0.09) (a) and −1.34 for PC3 (logrank chi-square: 8.92, p = 0.002) (b).
Figure 2Kaplan-Meier survival curves for recurrence free probability (RFP). Subgroups of low and high risk were determined by a cut-off value of 1.11 for PC1 (logrank chi-square: 7.09, p = 0.007) (a), female gender (logrank chi-square: 3.82, p = 0.05) (b) and a cut-off value of 3.4 for SUVmax (logrank chi-square: 6.75, p = 0.009) (c).
Figure 3Kaplan-Meier survival curves for distant control (DC). Subgroups of low and high risk were determined by a cut-off value of 1.11 for PC1 (logrank chi-square: 11.62, p = 0.0006) (a), −0.28 for PC4 (logrank chi-square: 6.27, p = 0.01) (b) and 7.6 for SUVmax (logrank chi-square: 6.22, p = 0.01).
Figure 4Kaplan-Meier survival curves for disease specific survival (DSS). Subgroups of low and high risk were determined by a cut-off value of 0.2 for PC2 (logrank chi-square: 4.08, p = 0.04) (a) and −0.98 for PC3 (logrank chi-square: 4.21, p = 0.04) (b).
Figure 5Kaplan-Meier survival curve for regional control (RC). Subgroups of low and high risk were determined by a cut-off value of −0.09 for PC4 (logrank chi-square: 6.19, p = 0.01).
Figure 6Screenshot of the texture analysis software applied on a staging PET/CT study for a NSCLC patient before SBRT therapy. On the left is the CT image and on the right, is the PET image of the PET/CT at the exact same level. The manual contouring of the right lower lobe tumor on both images is noted. There was an event of distant metastasis and death. SUVmax = 1.9. The significantly low SUVmax failed to predict the poor clinical outcome as evidenced by the development of distant metastasis and ultimately death.
Figure 7Screenshot of the texture analysis software applied on a staging PET/CT study for a NSCLC patient before SBRT therapy. On the left is the CT image and on the right, is the PET image of the PET/CT at the exact same level. The manual contouring of the tumor on both images is noted. There was no clinical event. SUVmax = 11.4. In comparison to the patient in the Fig. 1, the higher SUVmax did not correlate with the absence of clinical event.